Norwood Abbey implements commercialization phase for needle-free drug delivery

By Elaine Rigoli

Tampa, Fla., Aug. 28 - Norwood Abbey Ltd. said Monday that the commercialization phase of its needle-free drug-delivery device technology is gaining momentum. In particular, the results include a substantial reduction in the size/weight dimensions of the prospective devices and considerable progress in the delivery of varying volumes of different compounds.

The company has previously advised that it has entered into a license agreement with the Massachusetts Institute of Technology. The license provides Norwood Abbey with an exclusive worldwide license over all technological developments emerging from the contracted works programs in needle-free and micro-needle drug-delivery device technology.

The company has previously confirmed the successful completion of a prototype single-shot needle-free drug delivery device for use in humans.

The creation of the single-shot needle-free device presents Norwood with opportunities to participate in the delivery of vaccines to humans.

The company noted that vaccine companies have, for some years, been seeking a needle-free solution.

Norwood Abbey is a medical technologies company based in Victoria, Australia.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.